NCT06672952View on ClinicalTrials.gov

Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Exercise PerformanceExercise RecoveryCognitive FunctionNitric OxideBlood FlowEndurance Exercise
Interventions
DIETARY_SUPPLEMENT

400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.

DIETARY_SUPPLEMENT

Placebo

The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.

DIETARY_SUPPLEMENT

200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.

Trial Locations (1)

63301

Lindenwood University, Saint Charles

All Listed Sponsors
collaborator

Increnovo, LLC

INDUSTRY

lead

Lindenwood University

OTHER

NCT06672952 - Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators | Biotech Hunter | Biotech Hunter